European Finance News

Interhyp AG (FRA:IYP) 3rd Quarter 2008: Interhyp Increased Closed Mortgage Volume To 1.559 billion Euros, Market Share Rises To 3.5 Percent

🕔11/12/2008 5:03:02 PM

Interhyp AG (FRA:IYP) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

Kitron ASA (OSL:KIT) Profit Before Tax More Than Tripled

🕔11/12/2008 5:03:01 PM

Kitron ASA (OSL:KIT) Revenue amounted to NOK 483.7 million in the third quarter of 2008, representing 24 per cent increase over the same period in 2007. Profit before tax was NOK 29.3 million, which was more than three times the result in third quarter in 2007 (NOK 8.7 million). Order intake increased by 52 per cent compared to third quarter 2007.

Read Full Article

Storebrand ASA (OSL:STB) Storebrand: CAPITAL MARKETS DAY

🕔11/12/2008 5:03:01 PM

Storebrand ASA (OSL:STB) Storebrand will today arrange a Capital Markets Day in Oslo. All presentations is attached to this announcement, and can also be found on Storebrand`s web site www.storebrand.no/ir.

Read Full Article

OncoMethylome Sciences (EBR:ONCOB) Licenses Methylation Technologies To Qiagen for Commercializing Epigenetic Applications For The Scientific Research Market

🕔11/12/2008 5:03:01 PM

OncoMethylome Sciences (EBR:ONCOB) Liège, Belgium - November 12, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has signed a world-wide, non-exclusive license agreement with QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). Under this agreement, QIAGEN has licensed certain of OncoMethylome's methylation technologies for use in certain of QIAGEN's future products. These products will expand, among others, QIAGEN's EpiTect product line. The agreement specifically covers the use of OncoMethylome's patented Methylation-Specific PCR (MSP) technology, the most widely applied epigenetic technology, for the scientific research market. Under the terms of the agreement, QIAGEN will pay OncoMethylome an upfront fee plus royalties from future sales of products utilizing this technology. Other terms of the agreement were not disclosed.

Read Full Article

H. Lundbeck (CPH:LUN) Lundbeck Increases Its Research And Development Investments And Expects To Meet Its Financial Guidance For 2008

🕔11/12/2008 5:03:01 PM

H. Lundbeck (CPH:LUN) Sales of Cipralex® and Azilect® were up by 21% and 42%, respectively, at constant exchange rates in Q3 2008, and Ebixa® sales rose by 12% in Q3 2008 compared with the year-earlier period. Revenue growth was driven by increases in the markets in Europe and in International Markets, with both segments recording growth of 12% at constant exchange rates in Q3 2008 relative to Q3 2007.

Read Full Article

Wienerberger AG (WBAG:WIE) Wienerberger Has Clear Strategy For The Weak Market Environment

🕔11/12/2008 5:03:00 PM

Wienerberger AG (WBAG:WIE) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Read Full Article

Eitzen Maritime Services ASA (OSL:EMS) Mandatory Notification Of Trade

🕔11/12/2008 5:03:00 PM

Eitzen Maritime Services ASA (OSL:EMS) Knut Abrahamsen, CFO of Eitzen Maritime Services ASA, has on 11 November 2008 acquired 45,000 shares in Eitzen Maritime Services ASA at price NOK 1.24 pr. share. Total holding after the acquisition is 572,200 shares and 642,900 options.

Read Full Article